Burn Wound Clinical Trial
Official title:
A First-In-Human Pilot Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds
Verified date | May 2019 |
Source | Rogers Sciences Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this first-in-human, early feasibility study is to assess safety and feasibility of the Low-Irradiance Monochromatic Biostimulation (LIMB) System as a phototherapeutic intervention for the management of acute burn wounds. The prototype LIMB device will be evaluated for the occurrence of adverse events (treatment-related or otherwise) of the LIMB System, a portable, wearable, light-emitting system developed by Rogers Sciences, Inc. (RSI). The device will be administered in the small feasibility pilot to confirm design, usability and operating specifications that will inform procedures and endpoints of a subsequent large, multicenter clinical trial.
Status | Recruiting |
Enrollment | 12 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 21 Years |
Eligibility |
Inclusion Criteria: - Patients receiving care at Shriners Hospitals for Children-Boston for a skin tissue injury. - Patients who have at least one wound with exposed area sufficient, in the Investigator's opinion, to receive LIMB therapy. - Willing and able to adhere to daily LIMB therapy protocol. Exclusion Criteria: - Patients deemed not medically stable by the treating Investigator. - Patients with clinical signs and symptoms of systemic infection at baseline. - Patients with burn wounds limited to their head and genitalia. - Patients who, in the opinion of the Investigator, will not require daily dressing changes. - Patients receiving photosensitizing agents that result in cutaneous phototoxicity prior to enrollment. Patients who have received one or more of the following photosensitizers cannot be enrolled into the study: photofrin, amiodarone, chloropromazine, fluoroquinolone antibiotics, thiazide diuretics, quinine, demethylchlortetracycline, psoralens, nalidixic acid, tetracycline, naproxen. - Patients currently enrolled or participating in another investigational device, drug or biological trial within 30 days of the Screening Visit. - Patients currently receiving any bandages or devices containing silver compounds. - Patients on a ventilator, who have fluid resuscitation or are in any terminal condition. |
Country | Name | City | State |
---|---|---|---|
United States | Shriners Hospitals for Children-Boston | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Rogers Sciences Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Pain as Assessed by Checklist Pain Behavior Scale | To evaluate the change in participant's pain score during LIMB phototherapy treatment. Pain assessments taken daily at dressing change. | up to 7 days | |
Primary | Occurrence of Adverse Events from LIMB Phototherapy as Assessed by CTCAE v4.0 | To evaluate the occurrence of adverse events (treatment-related or otherwise) from LIMB phototherapy from the time of device application up to 7 days. Reporting consistent with CTCAE v4.0. Duration of LIMB phototherapy can be shortened per discretion of treating Investigator. | up to 7 days | |
Secondary | Change in Bioburden assessed through Wound Culture | To evaluate the effect of LIMB phototherapy on microbial bioburden. Wound culture specimens are collected at each daily dressing change to measure the change in microbial bioburden when compared to baseline. | up to 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04277182 -
Effect of Propolis Application on Burn Healing
|
N/A | |
Enrolling by invitation |
NCT00978705 -
Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood
|
Phase 3 | |
Withdrawn |
NCT03675568 -
Non-cultured Autologous Keratinocyte Suspension Versus Traditional Split Skin Graft for Burn Wounds Treatment
|
N/A | |
Active, not recruiting |
NCT04828304 -
PLASOMA Ultimate Safety & Efficacy Study
|
N/A | |
Not yet recruiting |
NCT05649332 -
Study to Evaluate the Performance and Safety of the Medical Device Argogen
|
N/A | |
Recruiting |
NCT05593523 -
Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes
|
||
Completed |
NCT06280053 -
HealiAid in the Treatment of Different Wounds
|
N/A | |
Enrolling by invitation |
NCT06103409 -
MSCs for the Treatment of Burn Wounds
|
Phase 1/Phase 2 | |
Recruiting |
NCT05796492 -
Ultrasound Treatment on Wound Healing Time
|
N/A | |
Enrolling by invitation |
NCT04725071 -
Immunonutrition Supplementation for Improved Burn Wound Healing in Older Adults
|
N/A | |
Suspended |
NCT02577120 -
Wound Healing Endpoint and Recurrence
|
Phase 4 | |
Active, not recruiting |
NCT05341427 -
DEVELOPMENT OF A CLINICAL PREDICTION RULES TO IDENTIFY EFFICACY OF PULSED ELECTROMAGNETIC THERAPY ON BURN WOUND HEALING
|
N/A | |
Completed |
NCT04753723 -
The Use of a Platform Wound Device for Reducing Infection
|
Phase 4 | |
Terminated |
NCT03723590 -
A Clinical Evaluation of an Esterified Hyaluronic Acid Matrix in Burn Patients for STSG
|
N/A | |
Not yet recruiting |
NCT04011306 -
A Feasibility Study of a Novel Phototherapy System for the Management of Acute Burns
|
N/A | |
Recruiting |
NCT05404191 -
Prediction Rules for Low Level Laser on Burn Wounds
|
N/A | |
Completed |
NCT02982096 -
Study Comparing Healing With Epidermal Fractional Blistergrafting (CellutomeTM) to Acellular Technique
|
N/A |